AU2003265522A1 - FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF - Google Patents
FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOFInfo
- Publication number
- AU2003265522A1 AU2003265522A1 AU2003265522A AU2003265522A AU2003265522A1 AU 2003265522 A1 AU2003265522 A1 AU 2003265522A1 AU 2003265522 A AU2003265522 A AU 2003265522A AU 2003265522 A AU2003265522 A AU 2003265522A AU 2003265522 A1 AU2003265522 A1 AU 2003265522A1
- Authority
- AU
- Australia
- Prior art keywords
- fcgammariib
- methods
- specific antibodies
- antibodies
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/026071 WO2005018669A1 (en) | 2003-08-18 | 2003-08-18 | Fcϝriib-specific antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003265522A1 true AU2003265522A1 (en) | 2005-03-10 |
Family
ID=34215340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003265522A Abandoned AU2003265522A1 (en) | 2003-08-18 | 2003-08-18 | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003265522A1 (en) |
WO (1) | WO2005018669A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1761563A4 (en) | 2004-05-10 | 2008-05-14 | Macrogenics Inc | HUMANIZED Fc gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
ES2530265T3 (en) | 2005-07-21 | 2015-02-27 | Genmab A/S | Binding potency assays of an antibody drug substance to an FC receptor |
EP2573114B1 (en) | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
CA2656224C (en) * | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
WO2009111648A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
KR101614494B1 (en) | 2008-04-02 | 2016-04-22 | 마크로제닉스, 인크. | Bcr-complex-specific antibodies and methods of using same |
EP2247304B1 (en) | 2008-04-02 | 2016-05-25 | MacroGenics, Inc. | Her2/neu-specific antibodies and methods of using same |
EP2282770B1 (en) | 2008-06-04 | 2018-03-07 | MacroGenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
ES2672121T3 (en) | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polypeptides containing Fc region that have an enhanced effector function due to alterations in the degree of fucosylation, and methods for their use |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
LT2542256T (en) | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
EP2837637A1 (en) * | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
GB2526139A (en) * | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
WO2016062891A1 (en) * | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION |
MX2018012433A (en) | 2016-04-15 | 2019-03-01 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof. |
WO2019234576A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
KR20230121772A (en) | 2020-12-18 | 2023-08-21 | 람카프 바이오 베타 엘티디. | Bispecific antibodies to CEACAM5 and CD47 |
AU2022325950A1 (en) | 2021-08-11 | 2024-02-22 | Viela Bio, Inc. | Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
-
2003
- 2003-08-18 WO PCT/US2003/026071 patent/WO2005018669A1/en active Application Filing
- 2003-08-18 AU AU2003265522A patent/AU2003265522A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005018669A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003265522A1 (en) | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
AU2003217870A1 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003225669A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003225668A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003275311A1 (en) | Solid micro-perforators and methods of use | |
AU2003213673A1 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1482984A4 (en) | Surrogate antibodies and methods of preparation and use thereof | |
IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
IL178593A (en) | Fcγriib-specific antibodies and methods of use thereof | |
EP1841452B8 (en) | Single domain antibodies against tnfr1 and methods of use therefor | |
AU2003278832A1 (en) | Optical biosensors and methods of use thereof | |
WO2007070538A9 (en) | Anti-mn antibodies and methods of using same | |
AU2003235676A1 (en) | Tricyclic-bis-enone derivatives and methods of use thereof | |
AU2002258790A1 (en) | Novel microarrays and methods of use thereof | |
IL157142A0 (en) | Modified antibodies and methods of use | |
AU2002314466A1 (en) | Withasol and methods of use | |
EP1611123B8 (en) | Tie-2 modulators and methods of use | |
SI1587542T1 (en) | Use of anti-cd100 antibodies | |
AU2002340167A1 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
EP1639086A4 (en) | Rna interferases and methods of use thereof | |
AU2003277259A1 (en) | Immunoassay and method of use | |
AU2003259717A1 (en) | Modulators of rabggt and methods of use thereof | |
EP1476150A4 (en) | Carboxyfullerenes and methods of use thereof | |
EP1699485A4 (en) | Anti-hydroxylase antibodies and uses thereof | |
AU2003303926A1 (en) | Ceramics and methods of making the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |